NEW YORK--(

纽约--(

BUSINESS WIRE

商业热线

)--Yesterday, Crown Laboratories, Inc. ('Crown'), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. ('Revance') (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings..

)--昨天，希尔德资本投资组合公司、私人控股的全球护肤行业创新领导者皇冠实验室（Crown Laboratories，Inc.）宣布收购Revance Therapeutics，Inc.（Revance）（纳斯达克：RVNC），这是一家生物技术公司，旨在通过创新的美学和治疗产品树立医疗保健的新标准。。

Jeff Bedard, Founder and Chief Executive Officer of Crown commented, “We are excited to officially welcome Revance to the Crown family. This acquisition strengthens our leadership position and enhances our ability to deliver innovative solutions to customers, with what we believe is a comprehensive portfolio that represents the three pillars of facial aesthetics – relax, restore, and regenerate – and we will support these offerings with a highly trained and experienced sales force.

皇冠创始人兼首席执行官杰夫·贝达德（Jeff Bedard）评论道：“我们很高兴正式欢迎Revance加入皇冠家族。此次收购加强了我们的领导地位，增强了我们向客户提供创新解决方案的能力，我们相信这是一个全面的投资组合，代表了面部美学的三大支柱——放松、恢复和再生，我们将通过训练有素、经验丰富的销售人员来支持这些产品。

We are well-positioned to become a global leader in the aesthetics and skincare industry and will leverage our combined resources to create long-term value for our stakeholders.”.

我们有能力成为美学和护肤行业的全球领导者，并将利用我们的综合资源为利益相关者创造长期价值。”。

On behalf of Hildred, Co-Founders and Managing Partners Andrew Goldman and David Solomon said, “We are thrilled to celebrate the successful completion of this transaction and to commence the integration of two innovative companies that we believe will create a leading player in the dynamic skincare and aesthetics markets.

联合创始人兼管理合伙人安德鲁·戈德曼（AndrewGoldman）和大卫·所罗门（DavidSolomon）代表希尔德雷德（Hildred）表示：“我们很高兴庆祝这笔交易的成功完成，并开始整合两家创新公司，我们相信这两家公司将在充满活力的护肤品和美学市场上创造领先地位。

Crown remains committed to providing healthcare providers and aesthetic practices with outstanding science-based products. We are excited to bring together Revance’s and Crown’s aesthetic offerings, and we look forward to continuing Revance’s relationship with Teoxane to grow the RHA® Collection by Teoxane in the U.S.

皇冠仍然致力于为医疗保健提供者和美学实践提供卓越的科学产品。我们很高兴能将Revance和Crown的美学产品结合在一起，我们期待着Revance与Teoxane继续保持合作关系，以扩大Teoxane在美国的RHA®系列。

market.”.

市场。”。

Additional details on the deal closing can be found in the press release

有关交易完成的更多详细信息，请参阅新闻稿

HERE

在这里

.

.

About Crown

关于皇冠

Crown, a privately held, fully integrated global skincare company, is committed to developing and providing a diverse portfolio of aesthetic, premium and therapeutic skincare products that improve the quality of life for its consumers throughout their skincare journey. An innovative company focused on skin science for life, Crown's unyielding pursuit of delivering therapeutic excellence and enhanced patient outcomes is why it has become a leader in Dermatology and Aesthetics.

皇冠是一家私人控股、全面整合的全球护肤公司，致力于开发和提供多样化的美容、优质和治疗性护肤产品组合，以提高消费者在整个护肤过程中的生活质量。作为一家专注于终身皮肤科学的创新公司，Crown不屈不挠地追求卓越的治疗效果和提高患者的治疗效果，这就是为什么它成为皮肤病学和美学领域的领导者。

Crown has been listed on the Inc. 5000 Fastest Growing Privately Held Companies List for eleven years and has expanded its distribution to over 50 countries. For more information, visit .

。有关更多信息，请访问。

www.crownlaboratories.com

www.crownlaboratories.com

.

.

The 'Crown' logo, PanOxyl and Blue Lizard are registered trademarks of Crown Laboratories, Inc. SkinPen and StriVectin are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company, Inc., respectively.

“Crown”徽标、PanOxyl和Blue Lizard是Crown Laboratories，Inc.的注册商标。SkinPen和StriVectin分别是Bellus Medical，LLC和StriVectin Operating Company，Inc.的注册商标。

About Revance

关于Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers.

Revance是一家生物技术公司，通过创新的美学和治疗产品，提高了患者的治疗效果和医生的体验，为医疗保健树立了新的标准。Revance的产品组合包括用于注射的DAXXIFY（DaxibotulinumtoxinA lanm）和RHA真皮填充剂系列。

RHA.

RHA。

®

®

technology is proprietary to and manufactured in Switzerland by Teoxane SA. Revance is an independent distributor of Teoxane SA for the RHA® Collection of dermal fillers for U.S. distribution. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.

该技术由Teoxane SA在瑞士拥有并制造。Revance是Teoxane SA的独立经销商，负责RHA®真皮填充物的美国销售。Revance还与Viatris Inc.合作开发注射用onabotulinumtoxinA的生物仿制药，并与上海复星制药合作将DAXXIFY在中国商业化。

Revance’s global headquarters and experience center are located in Nashville, Tennessee. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DAXXIFYCervicalDystonia.com, or connect with Revance on LinkedIn..

Revance的全球总部和体验中心位于田纳西州纳什维尔。更多信息，请访问Revance.com、revanceametics.com、DAXXIFY.com、HCP。DAXXIFYCervicalDystonia.com，或在LinkedIn上与Revance联系。。

“Revance,” the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid

“Revance”、“Revance徽标”和DAXXIFY是Revance Therapeutics，Inc.弹性透明质酸的注册商标

®

®

and RHA are trademarks of TEOXANE SA.

和RHA是TEOXANE SA的商标。

About Hildred Capital

Hildred Capital is a healthcare-focused private equity firm that specializes in operationally intensive, control-oriented investments in lower middle-market companies. Hildred partners with innovative and growth-oriented management teams to build high quality businesses. The Hildred team possesses extensive experience across the healthcare industry, and seeks to leverage its unique blend of strategic, financial, commercial and operational acumen to drive strategic growth and create value for its portfolio companies and investment partners.

Hildred Capital是一家专注于医疗保健的私人股本公司，专门从事中低端市场公司的运营密集型控制型投资。。Hildred团队在整个医疗保健行业拥有丰富的经验，并寻求利用其独特的战略、财务、商业和运营敏锐度来推动战略增长，并为其投资组合公司和投资伙伴创造价值。

Hildred currently has more than $2.65 billion in assets under management. For more information, please visit .

希尔德雷德目前管理的资产超过26.5亿美元。有关更多信息，请访问。

www.hildred.com

www.hildred.com

and follow the firm on

跟随公司前进

LinkedIn.

LinkedIn。